The North America Autoimmune Disease Therapeutics Market would witness market growth of 3.72% CAGR during the forecast period (2019-2025).
Approximately 50 million Americans suffer from autoimmune diseases, according to the National Institute of Health. The diseases are estimated to be one of the top 10 causes of death in females under the age of 65 and are the second largest cause of chronic disease. It is also the top cause of morbidity in females in the U.S. There are more than 80 clinically distinct types of autoimmune diseases recognized to date. Some of the prevalent kinds of autoimmune diseases are Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel illness, and due to the increasing autoimmune disease incidence, the demand for drugs used in autoimmune disease treatment is also increasing.
Based on Indication, the market is segmented into Rheumatic Disease, Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease, and Other Indications. Based on Drug Class, the market is segmented into Anti-Inflammatory, Anti-Hyperglycemics, NSAIDs (Nonsteroidal anti-inflammatory drugs), Interferons and Other Drugs. Based on the Distribution Channel, the market is segmented into Hospital Pharmacy, Online and Retail Pharmacies & Drug Stores. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include ABBOTT Laboratories, Bio-Rad Laboratories, Inc., Johnson and Johnson, GlaxoSmithKline PLC (GSK), Pfizer, Inc., Merck & Co., Inc., Bayer AG, AbbVie, Inc., Amgen, Inc. and Novartis AG.
By Indication
By Drug Class
By Distribution Channel
By Country
Companies Profiled
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
